脂质体两性霉素B与利什曼病：剂量与反应
Liposomal amphotericin B and leishmaniasis: dose and response.
作者信息
Sundar Shyam, Chakravarty Jaya
机构信息
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.
出版信息
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.
Abstract
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
摘要
脂质体两性霉素B已越来越频繁地用于治疗内脏利什曼病（VL）。它是地中海地区免疫功能正常患者的首选治疗药物，也是HIV/VL合并感染的首选药物。尽管寄生虫的易感性存在区域差异，但20mg/kg的总剂量对免疫功能正常的患者有效。迫切需要对脂质体两性霉素B治疗HIV-VL合并感染患者及二级预防进行随机临床试验，以优化该亚组的治疗。随着脂质体两性霉素B在流行地区以优惠价格供应，短程联合治疗可能成为一种可行的替代方案。
相似文献
1
Liposomal amphotericin B and leishmaniasis: dose and response.脂质体两性霉素B与利什曼病：剂量与反应
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.
2
Liposomal amphotericin B for the treatment of visceral leishmaniasis.脂质体两性霉素B用于治疗内脏利什曼病。
Clin Infect Dis. 2006 Oct 1;43(7):917-24. doi: 10.1086/507530. Epub 2006 Aug 28.
3
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.1型人类免疫缺陷病毒（HIV-1）与婴儿利什曼原虫合并感染患者内脏利什曼病治疗失败时寄生虫对两性霉素B的敏感性
Clin Infect Dis. 2009 Jan 15;48(2):e16-22. doi: 10.1086/595710.
4
Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.脂质体两性霉素 B 治疗人免疫缺陷病毒合并内脏利什曼病患者：印度比哈尔邦的 2 年治疗结局。
Clin Infect Dis. 2011 Oct;53(7):e91-8. doi: 10.1093/cid/cir521.
5
Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?脂质体两性霉素 B 治疗苏丹东部复杂内脏利什曼病（黑热病）：这种被忽视疾病的治疗效果如何？
Trop Med Int Health. 2014 Feb;19(2):146-52. doi: 10.1111/tmi.12238. Epub 2014 Jan 17.
6
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.埃塞俄比亚西北部脂质体两性霉素B治疗无HIV患者复杂性内脏利什曼病的安全性和疗效
BMC Infect Dis. 2016 Oct 10;16(1):548. doi: 10.1186/s12879-016-1746-1.
7
Current and emerging medications for the treatment of leishmaniasis.目前和新兴的治疗利什曼病的药物。
Expert Opin Pharmacother. 2019 Jul;20(10):1251-1265. doi: 10.1080/14656566.2019.1609940. Epub 2019 May 7.
8
Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.印度比哈尔邦一家三级护理中心脂质体两性霉素B治疗儿童和青少年内脏利什曼病的疗效和安全性
Am J Trop Med Hyg. 2017 Nov;97(5):1498-1502. doi: 10.4269/ajtmh.17-0094. Epub 2017 Oct 10.
9
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.利用重点药物警戒确保孟加拉国国家黑热病消除规划中抗利什曼原虫药物的患者安全。
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.
10
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.评估脂质体两性霉素 B 和米替福新联合治疗内脏利什曼病后皮肤利什曼病的疗效和安全性。
J Infect Dis. 2020 Feb 3;221(4):608-617. doi: 10.1093/infdis/jiz486.
引用本文的文献
1
New insights into the life cycle, host cell tropism, and infection amplification of spp.关于[物种名称]生命周期、宿主细胞嗜性和感染扩增的新见解
Infect Immun. 2025 Jul 8;93(7):e0012325. doi: 10.1128/iai.00123-25. Epub 2025 Jun 13.
2
Navigating the Parasitic Landscape: Insights into Infection Patterns and Public Health Strategies in West Africa.探索寄生虫领域：深入了解西非的感染模式与公共卫生策略
Trop Med Infect Dis. 2025 May 6;10(5):125. doi: 10.3390/tropicalmed10050125.
3
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.对抗耐多药结核病的创新策略：药物递送系统与治疗的进展
Microorganisms. 2025 Mar 24;13(4):722. doi: 10.3390/microorganisms13040722.
4
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.肠外纳米载体与给药装置的进展：全面综述
Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640.
5
Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.抗利什曼原虫药物的进展：作用机制、挑战与前景
PLoS Negl Trop Dis. 2025 Jan 3;19(1):e0012735. doi: 10.1371/journal.pntd.0012735. eCollection 2025 Jan.
6
Global Lipidomics Reveals the Lipid Composition Heterogeneity of Extracellular Vesicles from Drug-Resistant .全球脂质组学揭示耐药性细胞外囊泡的脂质组成异质性
Metabolites. 2024 Nov 25;14(12):658. doi: 10.3390/metabo14120658.
7
Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.用于治疗被忽视热带病的联合疗法及载有植物化学物质的纳米系统
Pharmaceutics. 2024 Sep 24;16(10):1239. doi: 10.3390/pharmaceutics16101239.
8
Leishmania major-induced alteration of host cellular and systemic copper homeostasis drives the fate of infection.利什曼原虫诱导的宿主细胞和全身铜稳态改变决定了感染的命运。
Commun Biol. 2024 Sep 30;7(1):1226. doi: 10.1038/s42003-024-06716-2.
9
Understanding nanoparticle-liver interactions in nanomedicine.纳米医学中纳米颗粒与肝脏的相互作用研究
Expert Opin Drug Deliv. 2024 Jun;21(6):829-843. doi: 10.1080/17425247.2024.2375400. Epub 2024 Jul 4.
10
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.抗利什曼病疫苗设计技术：当前挑战与启示
Curr Drug Discov Technol. 2025;22(2):e240524230315. doi: 10.2174/0115701638291767240513113400.
本文引用的文献
1
Single-dose liposomal amphotericin B for visceral leishmaniasis in India.印度单剂量脂质体两性霉素 B 治疗内脏利什曼病。
N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.
2
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.印度比哈尔邦治疗内脏利什曼病的人体测量学给药及药物成本计算
Trop Med Int Health. 2009 Jan;14(1):88-92. doi: 10.1111/j.1365-3156.2008.02195.x. Epub 2008 Dec 11.
3
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.印度内脏利什曼病的新治疗方法：单剂量脂质体两性霉素B继以短疗程口服米替福新。
Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.
4
Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.脂质体两性霉素B用于HIV感染患者内脏利什曼病二级预防的疗效。
J Antimicrob Chemother. 2007 Oct;60(4):837-42. doi: 10.1093/jac/dkm294. Epub 2007 Aug 7.
5
Injectable paromomycin for Visceral leishmaniasis in India.印度用于治疗内脏利什曼病的注射用巴龙霉素
N Engl J Med. 2007 Jun 21;356(25):2571-81. doi: 10.1056/NEJMoa066536.
6
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.在印度进行的一项关于sitamaquine治疗内脏利什曼病的II期剂量范围研究。
Am J Trop Med Hyg. 2005 Dec;73(6):1005-11.
7
Treatment of visceral leishmaniasis.内脏利什曼病的治疗。
Expert Opin Pharmacother. 2005 Dec;6(16):2821-9. doi: 10.1517/14656566.6.16.2821.
8
A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.在肯尼亚进行的一项关于sitamaquine治疗内脏利什曼病的II期剂量递增研究。
Am J Trop Med Hyg. 2005 Nov;73(5):871-6.
9
Risk factors for kala-azar in Bangladesh.孟加拉国黑热病的风险因素。
Emerg Infect Dis. 2005 May;11(5):655-62. doi: 10.3201/eid1105.040718.
10
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?儿童内脏利什曼病的治疗：两性霉素B还是五价锑化合物？
Int J Antimicrob Agents. 2005 Jan;25(1):26-30. doi: 10.1016/j.ijantimicag.2004.09.011.
Zotero 插件